Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy.
Expert Opin Investig Drugs
; 33(6): 613-625, 2024 Jun.
Article
in En
| MEDLINE
| ID: mdl-38775361
ABSTRACT
INTRODUCTION:
The global prevalence of colorectal cancer highlights the need to enhance treatment strategies for improved patient outcomes. The pivotal role of epidermal growth factor receptor (EGFR) signaling in regulating cellular processes for this disease pinpoints its value as a therapeutic target, despite the emergence of resistance mechanisms over time. AREAS COVERED This review discusses the clinical evidence supporting the use of EGFR inhibitors in molecularly-selected patients based on molecular characteristics (notably BRAF V600E and KRAS G12C) including combination approaches targeting different points in in the signaling pathway, as well as strategies such as EGFR inhibitor rechallenge. The role of HER2 inhibitors and emerging approaches such as bispecific antibodies are also reviewed. EXPERT OPINION Recently, inhibitors targeting the KRAS G12C variant have emerged, albeit with modest monotherapy activity compared to other tumor types, emphasizing the influence of histologic origins on the EGFR signaling pathway. Integration of EGFR inhibitors into precision medicine has facilitated tailored therapies addressing resistance mechanisms. Patient selection for EGFR inhibitor rechallenge guided by ctDNA findings is crucial, with ongoing investigations exploring novel combinations to enhance EGFR blockade, highlighting the transformative potential of precision medicine in shaping the future of mCRC treatment toward personalized and targeted approaches.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Colorectal Neoplasms
/
Signal Transduction
/
Drug Resistance, Neoplasm
/
Precision Medicine
/
Molecular Targeted Therapy
/
ErbB Receptors
/
Antineoplastic Agents
Limits:
Animals
/
Humans
Language:
En
Journal:
Expert Opin Investig Drugs
Journal subject:
TERAPIA POR MEDICAMENTOS
Year:
2024
Type:
Article
Affiliation country:
Spain